TriSalus Life SciencesTLSI
TLSI
About: TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Employees: 110
0
Funds holding %
of 7,428 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
750% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 2
176% more capital invested
Capital invested by funds: $16.9M [Q1] → $46.7M (+$29.8M) [Q2]
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
33% more funds holding
Funds holding: 36 [Q1] → 48 (+12) [Q2]
12.59% more ownership
Funds ownership: 10.06% [Q1] → 22.65% (+12.59%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for TLSI.
Financial journalist opinion
Based on 6 articles about TLSI published over the past 30 days
Neutral
Seeking Alpha
1 week ago
TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 AM ET Company Participants David B. Patience - Chief Financial Officer Jeremy Feffer - Corporate Participant Mary T.
Negative
Zacks Investment Research
1 week ago
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.21 per share a year ago.
Neutral
Business Wire
1 week ago
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. “TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical ado.
Neutral
Business Wire
2 weeks ago
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) technology in thyroid parenchymal embolization, a new application for the treatment of patients with sympt.
Neutral
Business Wire
3 weeks ago
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 9:00 a.m. ET. Management will also host investor meetings dur.
Neutral
Business Wire
3 weeks ago
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy, announced today that it will host a conference call and webcast on Tuesday August 12, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. A press release detailing the results will b.
Neutral
Business Wire
1 month ago
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company focused on improving outcomes for patients with solid tumors, announced the completion of its previously disclosed exchange offer and consent solicitation for its Preferred Stock. The offer expired one minute after 11:59 p.m. EDT on July 23, 2025. Under the terms of the offer, TriSalus provided holders of its Preferred Stock the option to exchange each preferred share for 3.3 shares of its common stock.
Neutral
Business Wire
2 months ago
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy (“TriSalus” or the “Company”), today announced that it has commenced an exchange offer and consent solicitation involving its Series A Convertible Preferred Stock (the “Preferred Stock”) identified in the Prospectus/Offer to Exchange (as defined below). TriSal.
Neutral
Business Wire
2 months ago
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, is excited to announce the launch of the TriNav® FLX Infusion System, the latest addition to the TriNav Portfolio. TriNav FLX, with enhanced trackability, significantly expands our existing portfolio of TriNav pr.
Neutral
Business Wire
2 months ago
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice Presi.
Charts implemented using Lightweight Charts™